-
Mashup Score: 1FDA Grants Orphan Drug Designation to LSTA1 in Osteosarcoma - 3 day(s) ago
LSTA1 has been granted orphan drug designation by the FDA for the treatment of patients with osteosarcoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1FDA Grants Orphan Drug Designation to LSTA1 in Osteosarcoma - 11 day(s) ago
LSTA1 has been granted orphan drug designation by the FDA for the treatment of patients with osteosarcoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1FDA Grants Orphan Drug Designation to LSTA1 in Osteosarcoma - 15 day(s) ago
LSTA1 has been granted orphan drug designation by the FDA for the treatment of patients with osteosarcoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
LSTA1 has received rare pediatric disease designation from the FDA for the treatment of patients with osteosarcoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
LSTA1 has received rare pediatric disease designation from the FDA for the treatment of patients with osteosarcoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
LSTA1 has received rare pediatric disease designation from the FDA for the treatment of patients with osteosarcoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
LSTA1 has received rare pediatric disease designation from the FDA for the treatment of patients with osteosarcoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Active Surveillance Is a Safe and Acceptable Treatment Alternative in Select D-TGCT - 2 month(s) ago
R. Lor Randall, MD, discusses the adequacy of active surveillance for select patients with diffuse-type tenosynovial giant cell tumor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Active Surveillance Is a Safe and Acceptable Treatment Alternative in Select D-TGCT - 2 month(s) ago
R. Lor Randall, MD, discusses the adequacy of active surveillance for select patients with diffuse-type tenosynovial giant cell tumor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Active Surveillance Is a Safe and Acceptable Treatment Alternative in Select D-TGCT - 2 month(s) ago
R. Lor Randall, MD, discusses the adequacy of active surveillance for select patients with diffuse-type tenosynovial giant cell tumor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
.@us_fda Grants Orphan Drug Designation to LSTA1 in Osteosarcoma #scmsm https://t.co/AFqAQxYtXk